NEW YORK – Investigators from TGen, working with City of Hope, Mayo Clinic, and other clinical collaborators, are gearing up to clinically validate and prove utility for their liquid biopsy method to monitor patients with early-stage cancer as they are treated, allowing doctors to better predict if they need additional interventions or may be effectively cured.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.